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In the brain, brief episodes of ischemia induce tolerance against a subsequent severe episode of ischemia. This phenomenon of 
endogenous neuroprotection is known as preconditioning-induced ischemic tolerance. The purpose of this review is to summa-
rize the current state of knowledge about mechanisms and potential applications of cerebral preconditioning and ischemic toler-
ance. Articles related to the terms ischemic preconditioning and ischemic tolerance were systematically searched via MEDLINE/
PubMed, and articles published in English related to the nervous system were selected and analyzed. The past two decades have 
provided interesting insights into the molecular mechanisms of this neuroprotective phenomenon. Although both rapid and 
delayed types of tolerance have been documented in experimental settings, the delayed type has been found to be more promi-
nent in the case of neuronal ischemic tolerance. Many intracellular signaling pathways have been implicated regarding ischemic 
preconditioning. Most of these are associated with membrane receptors, kinase cascades, and transcription factors. Moreover, 
ischemic tolerance can be induced by exposing animals or cells to diverse types of endogenous and exogenous stimuli that are 
not necessarily hypoxic or ischemic in nature. These cross-tolerances raise the hope that, in the future, it will be possible to phar-
macologically activate or mimic ischemic tolerance in the human brain. Another promising approach is remote preconditioning 
in which preconditioning of one organ or system leads to the protection of a different (remote) organ that is difficult to target, 
such as the brain. The preconditioning strategy and related interventions can confer neuroprotection in experimental ischemia, 
and, thus, have promise for practical applications in cases of vascular neurosurgery and endo-vascular therapy.
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CEREBRAL ISCHEMIA/STROKE
The term ischemia (Greek iskhein to keep back + haema or hema 
blood) means a restriction in blood supply to a bodily organ or 
tissues. Interruption of blood flow to the brain or part(s) of the 
brain is known as cerebral ischemia or stroke. A stroke is a med-
ical emergency, which can cause permanent neurological dam-
age, complications, and death. More than 2,400 years ago, the 
father of medicine, Hippocrates, recognized and described stroke 
as the sudden onset of paralysis. In the past, stroke was referred 
to as cerebrovascular accident, but the term stroke is now pre-
ferred.
  Stroke causes 9% of all deaths around the world, is the third 
most common cause of death after ischemic heart disease and 
cancer, and may soon become the leading cause of death world-
wide. It is the leading cause of adult disability, because 76% of 
people in the United States and Europe survive their stroke [1].
  The central goal of therapy in acute ischemic stroke is to pre-
serve the area of oligemia in the ischemic penumbra. The area 
of oligemia can be preserved by limiting the severity of ischemic 
injury (i.e., neuronal protection) or by reducing the duration of 
ischemia (i.e., restoring blood flow to the compromised area). 
The ischemic cascade offers many points at which such inter-
ventions could be attempted. However, it has become increas-
ingly clear that therapeutic interventions targeting only part of 
the complex network of mediators that contribute to ischemic 
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brain damage produce only subtle effects on the outcome of 
stroke in clinical trials [2,3]. A solution to this problem could 
be derived from an understanding of the mechanisms by which 
the cell adapts to ischemic stress [4-7].
ISCHEMIC PRECONDITIONING AND ISCHEMIC 
TOLERANCE
Ischemic stress induces both harmful and protective responses, 
and the balance between these two responses determines cellu-
lar fate. If the stress is sublethal (i.e., below the threshold of dam-
age), protective mechanisms prevail. When another stress is re-
applied at the peak of the stress-controlling period, cells show 
better tolerance. This phenomenon is known as stress adapta-
tion or preconditioning, in which sublethal stress induces an 
adaptive response to subsequent lethal stress. In fact, this obser-
vation has long been expressed as “Adaptation to perturbations 
is the basis for homeostasis” (Cannon), “the general adaptation 
syndrome” (Selye), “The dose makes the poison” (Paracelsus) 
or “Poisons are stimulants in small doses” (Arndt-Schultz). This 
cellular response can be observed in a wide variety of species 
from bacteria to mammalian cells [8]. The terms precondition-
ing and tolerance were first introduced by Janoff [9] in a study 
of the shock model. Generally, preconditioning can be defined 
as “presenting a stressful but non-damaging stimulus to cells to 
induce an endogenous adaptive response which would help cells 
to tolerate subsequent severe stresses.” A condition of transient-
ly increased resistance to ischemic stress as a result of the acti-
vation of endogenous protective mechanisms by precondition-
ing is known as ischemic tolerance [10]. This novel phenome-
non has been described in a variety of organ systems, including 
the brain, heart, liver, intestine, lung, skeletal muscle, kidney and 
bladder [11-14]. Although it is generally assumed that the pre-
conditioning phenomenon was first described in the heart in 
the 1980s [11,15] and not until 1990 in the brain, in fact, Dahl 
and Balfour [16] first described this phenomenon in 1964 in 
relation to brain ischemia, 20 years before the classic cardiology 
experiments were published. Several reports in the late 1980s 
again drew attention to ischemic tolerance in the brain [17-18]. 
Since then, this phenomenon has been confirmed in many ani-
mal models of global [19] and focal ischemia [20], in in vitro 
brain slice preparations [21], in cultured primary neurons [22], 
and in human beings in the form of short episodes of ischemia 
without infarction, known as a transient ischemic attack (TIA) 
[23].
STIMULI THAT EVOKE NEURONAL ISCHEMIC 
TOLERANCE
Even though short episodes of cerebral ischemia or cerebral hy-
poxia were initially considered as prototypical preconditioning 
stimuli, subsequent studies have shown that ischemic tolerance 
can be induced by exposing animals or cells to diverse types of 
endogenous and exogenous stimuli that are not necessarily hy-
poxic or ischemic in nature [5]. These stimuli include spreading 
depression, hyperoxia, oxidative stress, prolonged hypoperfu-
sion, hypothermia, and hyperthermia. Therefore, one stressor 
can promote ‘cross-tolerance’ to another. The diversity of stimu-
li capable of inducing an ischemia-resistant phenotype in the 
brain indicates that the signaling pathways activated by these 
different triggers converge downstream on some common, fun-
damental mechanisms that ultimately account for the protection. 
Many exogenously delivered chemical preconditioning agents 
(e.g., inflammatory cytokines [24], anesthetics [25], and meta-
bolic inhibitors [26]) can also induce ischemic tolerance, which 
raises the hope that, it will be possible in the future to pharma-
cologically activate these distal pathways in the human brain. 
Moreover, physical exercise [27] and skeletal muscle [28] pre-
conditioning-induced neuroprotection against cerebral ischemia 
promise another attractive strategy, remote preconditioning, to 
protect organs that are highly susceptible to damage but that are 
difficult to target, such as the brain. However, the underlying 
complex molecular mechanisms of ischemic tolerance are still 
not well known.
MECHANISM OF ISCHEMIC TOLERANCE
Two temporally distinct types of ischemic tolerance are afford-
ed by sublethal pretreatment: early and delayed tolerance, the 
mechanisms of which may differ. In the early (or rapid) type, the 
trigger induces tolerance within minutes and is transient; in the 
delayed type, tolerance takes hours to days to become apparent 
and lasts for days to weeks. Although both types of ischemic 
tolerance have been found in the brain and in the heart, the time 
course of ischemic tolerance in the brain usually follows the de-
layed pattern; however, in the heart, the tolerance induced by 
ischemic preconditioning usually follows the rapid pattern, also 
known as classic preconditioning, which represents a marked 
difference between the heart and the brain. In general, it is wide-
ly accepted that early acquisition of tolerance is independent of 
protein synthesis, mediated by posttranslational modification, www.einj.or.kr    205
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and the effective duration is brief. Conversely, the general agree-
ment is that delayed induction of ischemic tolerance requires 
new protein synthesis and is sustained for a few days to weeks.
  To induce tolerance by means of ischemic episodes, three fac-
tors should be considered: 1) the duration, 2) the time interval, 
and 3) the number of episodes. First, the preconditioning stim-
uli must be severe enough to initiate a response, but not so se-
vere as to cause permanent damage. Second, some interval of 
time must exist between sublethal and lethal stress. Third, the 
number of short ischemic episodes should be considered for 
sufficient stimulation of the protective response against a lethal 
ischemic insult.
  Ischemia is an unspecific injury that causes disturbances in a 
multitude of cellular processes [29]. Therefore, induction of tol-
erance is most likely the result of several mechanisms and mo-
lecular pathways. In general, the process of tolerance induction 
can be divided into the following elements: sensors of the stress 
signal, transducers of the stimulus, and effectors of the tolerance 
[30]. First, the preconditioning stimulus must be recognized by 
cellular sensors so that the cells can be prepared for upcoming 
stress. Neurotransmitter and cytokine receptors, ion channels 
and redox-sensitive enzymes generally work as molecular sen-
sor of stress stimuli. These sensors activate enzymes, such as ki-
nase protein Ras, Raf, mitogen-activated protein kinase (MAPK) 
kinase (MEK), extracellular regulated kinase (ERK), Akt, and 
protein kinase C, and signaling molecules, such as nitric oxide 
(NO), diacylglycerol, inositol triphosphate, Ca
2+, and ceramide, 
which transduce the signal and initiate an adaptive response. 
Finally, effectors of the preconditioning response confer toler-
ance to cells or tissues through anti-excitotoxicity, anti-apopto-
sis, anti-inflammation, protection of mitochondria and increased 
anti-oxidant mechanisms [30-32]. The following is an overview 
of various components and the potential mechanisms that may 
responsible for ischemic tolerance.
The Membrane Receptors
Membrane stabilization to prevent toxic intracellular Ca
2+ levels 
could provide a first line of protection, because the intracellular 
accumulation of Ca
2+ through overactivation of Ca
2+ channels 
is the key trigger in neuronal excitotoxicity and death [33]. As 
in cardiac preconditioning, adenosine, adenosine A1 receptors, 
and adenosine triphosphate (ATP)-sensitive K
+ channels may 
play a role in neuronal preconditioning and early ischemic tol-
erance [34]. This hypothesis was supported by the fact that ade-
nosine uptake inhibition could potentiate ischemic tolerance 
[35] and that adenosine receptor antagonists were shown to 
block the ischemic tolerance phenomenon [36]. The proposed 
mechanism is as follows: a change in ATP-sensitive K
+ channels 
hyperpolarizes the neuronal cell membrane and thereby pro-
tects the neuron from detrimental depolarization.
  Glutamate has long been known to kill neurons through an 
N-methyl-D-aspartate (NMDA) receptor-mediated mecha-
nism. In contrast, preconditioning of neurons with subtoxic 
concentrations of NMDA protect neurons against subsequent 
glutamate-mediated excitotoxicity and in vitro ischemia [37]. 
One mechanism of NMDA mediated neuroprotection involves 
a rapid adaptation of the voltage-dependent calcium flux. An-
other mechanism involves the activation of NMDA receptors, 
which leads to the rapid release of brain-derived neurotrophic 
factor (BDNF) [38]. BDNF binds to and activates its cognate 
receptor, receptor tyrosine kinase B. Exactly how the neurons 
mediate neuroprotection by activation of the receptors is just 
beginning to be understood.
  The α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic 
acid receptor (AMPAR) activates the opening of an ionotropic 
channel, which permits the entry of intracellular sodium and 
the exit of potassium to the extracellular medium. Depending 
on the electrical charge originating from the amino acids that 
form the channel pore, passage of the calcium ion is also permit-
ted. Ischemic preconditioning induces a small, transient down-
regulation of AMPA receptor Ca
2+ ion gatekeeper subunit 
GluR2 mRNA expression and greatly attenuates subsequent 
ischemia-induced GluR2 mRNA and protein down-regulation, 
and neuronal death [39]. The suppression of GluR2 down-reg-
ulation was proposed as a mediator of ischemic tolerance in 
carbonic anhydrase (CA)1 hippocampal neurons. However, 
this hypothesis was challenged by the finding that GluR2 re-
duction also occurs in neurons without subsequent neuronal 
death [40]. Therefore, further studies are needed to clarify the 
role of AMPAR subunit changes in tolerance induction.
  Pharmacological stimulation of the γ-aminobutyric acid 
(GABA)-ergic system, a major inhibitory neurotransmitter sys-
tem, has been shown to protect vulnerable neurons against isch-
emic damage [41]. In 2003, Sommer et al. [42] showed that isch-
emic tolerance in the preconditioned gerbil hippocampus is as-
sociated with increased ligand binding to inhibitory GABAA 
receptors between 30 minutes and 48 hours of recirculation. A 
relative shift between excitatory and inhibitory neurotransmis-
sion may promote post-ischemic survival of CA1 neurons. The 
conclusion that functional suppression of excitatory neuro-206    www.einj.or.kr
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transmission by the GABA pathway contributes to cellular sur-
vival during ischemia appears justified.
  The delta opioid receptor was shown to be involved in both 
rapid and delayed hypoxic preconditioning-induced ischemic 
tolerance in cultured rat cortical neurons [43]. It was shown 
that the hypoxic preconditioning-induced ischemic tolerance 
effect could be blocked by a specific delta opioid receptor an-
tagonist, which suggests the involvement of these receptors; 
however, the molecular mechanism is not well understood.
Signal Transduction
How cells behave and answer to outside stress stimulation has 
been considered another important factor in ischemic tolerance 
induction. Second messenger molecules and related protein ki-
nase-cascades are probably the most widely studied components 
of the transmission of stress and survival signal.
  The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is be-
lieved to play a vital role in mediating survival signals in a wide 
range of neuronal cell types. The serine-threonine kinase Akt, 
also known as protein kinase B, is mainly activated in a PI3K 
manner by a variety of stimuli, including growth factors, trau-
matic brain injury [44], and ischemia [45]. Phosphorylation of 
Akt results in the full activation of its kinase activity and exerts 
a cell survival role via the phosphorylation of its many down-
stream targets, such as B-cell lymphoma 2 (Bcl-2) associated 
death protein, glycogen synthase kinase-3, pro-caspases-9, cy-
clic adenosine monophosphate (cAMP) response element-bind-
ing protein, and forkhead transcription factors. Numerous stud-
ies suggest that increased Akt activity induced by precondition-
ing is involved in ischemic tolerance. For example, Nakajima et 
al. [46] found that preconditioning prevents ischemia-induced 
neuronal death through persistent Akt activation in the pen-
umbra region of the rat brain. Wick et al. [47] demonstrated 
that neuroprotection by hypoxic preconditioning requires se-
quential activation of vascular endothelial growth factor (VEGF) 
receptor and Akt. Neurons incubated under hypoxic conditions 
showed increased levels of VEGF, VEGF receptor-2 (VEGFR-2), 
phosphorylated Akt, and ERK1. Incubation with a neutralizing 
anti-VEGF and anti-VEGFR-2 antibody, the PI3K inhibitor 
wortmannin, or antisense-Akt, reversed the resistance acquired 
by hypoxic preconditioning.
  Another type of signaling pathway, MAPK family is, also, 
thought to play an important role in the cellular adaptation to 
various stimuli, including ischemia. The MAPK family of pro-
line-directed serine-threonine kinases consists of ERK1/2, c-Jun 
N-terminal kinase (JNK), and p38 MAPK, which have been ex-
tensively studied regarding the ischemia/reperfusion related cell 
death and survival paradigm. It is generally suggested that 
ERK1/2 plays a positive role in cellular survival, growth, and 
differentiation; however, ERK1/2 has been reported to play a 
negative role in both in vivo and in vitro cerebral ischemia mod-
els [48,49]. Tauskela et al. [50] showed that MAPK did not change 
after in vitro ischemia, and pharmacological inhibition of 
MAPK by PD98059 did not block preconditioning-induced 
neuroprotection in cultured rat cortical neurons. These findings 
suggest the lack of involvement of MAPK in ischemic tolerance. 
In contrast, Gonzalez-Zulueta et al. [51] demonstrated the in-
volvement of the p21
ras/ERK1/2 signaling pathway in ischemic 
tolerance induced by oxygen-glucose deprivation (OGD) pre-
conditioning in matured primary cultured cortical neurons. They 
showed that blocking of MEK activity during the precondition-
ing paradigm by using an MEK inhibitor U0126 suppressed the 
induction of ischemic tolerance. JNK is activated by many stress 
stimuli and plays a key role in ischemic cell death. Zhang et al. 
[52] reported in a previous study that JNK3 is implicated in 
ischemic tolerance in vivo. They showed that JNK was nega-
tively regulated by preconditioning-induced active Akt. Inter-
estingly, p38 MAPK was reported to play a positive role in isch-
emic tolerance [53] and a negative role in the hypoxic precon-
ditioning of cortical neurons [43]. The role of MAPK cascades 
in neuronal death and survival seems to be complicated and 
might result from differences in experimental models, such as 
the type of cells, the age of neurons, the magnitude and timing 
of insults, and the type of insult [50,54].
  Protein kinase C (PKC) represents a family of second mes-
senger dependent serine/threonine kinases that are stimulated 
by Ca
2+ and/or phospholipid. At least 10 isoforms of PKC are 
known and are classified on the basis of their second messenger 
requirements. PKC signaling has been shown to be differential-
ly involved in preconditioning. Current data suggest that isch-
emic preconditioning enhances the down-regulation of cell sig-
naling mediated by PKC gamma and Ca
2+/calmodulin-depen-
dent protein kinases (CaMK) II, which enhances the normal-
ization of calcium homeostasis [55]. On the other hand, pre-
conditioning appears to specifically activate PKC delta and ep-
silon [56].
  Although NO production during ischemic stress is toxic, it 
may also be linked to ischemic tolerance [57]. Gidday et al. [58] 
reported that NO production by endothelial nitric oxide synthase 
(NOS) is important in the induction of ischemic tolerance in a www.einj.or.kr    207
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newborn rat hypoxic preconditioning model. Moreover, it was 
also shown that neuronal NOS (nNOS) mediated NO was in-
volved in anoxic preconditioning in a hippocampal slice model 
[59]. Production of NO depends on NMDA receptor activation 
[37], which activates nNOS. Increased NO can activate the Raf/
MEK/ERK cascade and can induce new protein synthesis [60]. 
In cell cultivation models, a major loss of neuroprotection is 
observed when NOS inhibitor and NMDA receptor antagonists 
are added during a preconditioning paradigm [37,51]. Similarly, 
inducible NOS (iNOS) is known to exacerbate ischemic damage 
in the brain [61]; however, iNOS induction has also been impli-
cated in tolerance induction pathways initiated by anesthetic 
preconditioning in the brain [25].
Inflammatory Cytokines and Ceramide
Inflammatory cytokines, particularly tumor necrosis factor-α 
(TNF-α), interleukin (IL)-1β, and IL-6, have been implicated in 
the mechanism involved in ischemic tolerance [62-64]. IL-1 re-
ceptor antagonists can block tolerance induced by brief priming 
ischemia [32]. Cytoprotective preconditioning with TNF-α in-
duces manganese superoxide dismutase (MnSOD). Preclinical 
stroke models and primary cultures of cortical neurons, cortical 
astrocytes and microvessel endothelial cells show that TNF-α 
and its downstream mediator ceramide are involved in tolerance 
signaling [62,65,66]. The activity of TNF-α at its membrane re-
ceptor leads to the generation of ceramide and to the release of 
nuclear factor-κB (NF-κB) from the inhibitor of the inhibitor 
(I)-κB complex. The translocation of NF-κB leads to the gene 
transcription of a variety of pro- and anti-apoptotic molecules 
[31]. Although ceramide has long been considered to induce 
cellular apoptosis, the exogenous application of subtoxic concen-
trations of ceramide can induce neuronal ischemic tolerance 
and act as a neuroprotective agent against lethal OGD stress 
[65,66].
Transcription Factors
Transcription factors are the link between kinase cascades and 
gene expression. Some of the most studied transcription factors 
include NF-κB, cAMP response element-binding protein, and 
the activator-protein 1 (AP-1) family.
  NF-κB is a dimeric transcription factor consisting of heterodi-
mers or homodimers of Rel proteins and is bound in the cyto-
plasm to inhibitory proteins of the I-κB family. NF-κB is acti-
vated by various signals, such as cytokines, neurotrophic fac-
tors, neurotransmitters, oxidative stress and intracellular eleva-
tion of Ca
2+. NF-κB plays a pivotal role in the induction of neu-
roprotective genes (e.g., MnSOD and Bcl-2) expressions, which 
are known to be related to tolerance induction [31]. It has been 
reported that the expression of NF-κB increases in three differ-
ent paradigms of ischemic tolerance induced by sublethal isch-
emia, epilepsy and polyunsaturated fatty acids [67]. Pretreat-
ment with NF-κB inhibitor or κB decoy DNA blocked NF-κB 
activity and eventually suppressed the neuroprotective effect of 
preconditioning. The AP-1 factor is a dimeric complex consist-
ing of the Fos and Jun families, which were originally known as 
protooncogenes. The activation of AP-1 occurs through phos-
phorylation of its components by JNK and p38 kinase cascades. 
A complex pattern of Fos and Jun protein expression seems to 
underlie tolerance induction and delayed neuronal death [68,69]. 
The available literatures indicates that the AP-1 transcription 
factor family plays a crucial role in both neuroprotection and 
neurodegeneration [70].
CLINICAL PROSPECTS AND FUTURE 
CHALLENGES
The preconditioning phenomenon has been successful as an 
experimental procedure for identifying the mechanisms respon-
sible for brain protection and regeneration. Important examples 
of strategies to modulate these mechanisms include erythropoi-
etin, activators of mitochondrial KATP channels, and volatile an-
esthetics. The phenomenon of ischemic tolerance has not only 
been found in cells, organs and animal experimental models; 
some clinical observational data indicate that this phenomenon 
may occur naturally in the human brain in the form of short 
episodes of ischemia without infarction, known as TIA. In a 
retrospective clinical study, Weih et al. [71]. evaluated 148 
stroke patients with and without antecedent TIA and found 
that TIA before stroke is associated with significantly less severe 
stroke on admission and improved outcomes on follow-up. 
Another retrospective study, which included more than 2000 
patients, confirmed these results 1 year later [72]. In support of 
these findings, studies using magnetic resonance imaging and 
neuroradiological analysis showed that ischemic stroke patients 
with prodromal TIA have significantly smaller ischemic lesions 
after stroke than those patients without TIA [73,74]. These ob-
servations suggest that endogenous preconditioning triggered 
by TIA is present in the human brain.
  Induction of ischemic tolerance in the brain has been suggest-
ed to be a promising clinical strategy for preparing the brain for 208    www.einj.or.kr
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situations of possible ischemia, such as cardiac or brain surgery 
and in patients with a high risk of stroke. However, because of 
ethical and safety concerns associated with ischemic precondi-
tioning, researchers are trying to identify a safer precondition-
ing stimulus that would be both practical and effective or a bio-
logical agent that can mimic preconditioning pharmacological-
ly. Many candidate pharmacological regulators of the stress re-
sponse and inducers of ischemic tolerance have been proposed 
[75-79], one of which is erythropoietin. Erythropoietin is ap-
proved for the treatment of anemia and seems safe and effective 
for critically ill patients who are anemic and have experienced 
trauma [80]. The iron chelator desferrioxamine is clinically ap-
proved for various indications, including thalassemia and other 
iron-overload syndromes. Various inhalational anesthetics used 
in human beings (e.g., sevoflurane) induce tolerance against 
brain ischemia and act as brain protectants after ischemia in 
preclinical experiments [81-83]. These compounds are safe and 
effective at eliciting early preconditioning in patients undergo-
ing coronary artery bypass graft surgery in randomized con-
trolled trials [84]. These drugs also elicit delayed precondition-
ing in human beings [85,86].
  Another promising approach is remote preconditioning in 
which preconditioning of one organ or system leads to protec-
tion of a different (remote) organ. The prototypical approach 
for remote preconditioning is the initiation of short ischemic 
insult(s) to a limb to protect organs such as the heart [87,88] and 
the brain [89,90]. Remote preconditioning might indicate a 
crosstalk between the brain and the rest of the body in response 
to stress through the peripheral nervous system or paracrine 
signal. Randomized clinical trials have already shown the effi-
cacy of this strategy for the heart [91,92]. Remote precondition-
ing is a particularly attractive strategy for protecting organs that 
are highly susceptible to damage but that are difficult to target, 
such as the brain.
  Although many researchers are actively characterizing the 
signaling mechanisms of ischemic preconditioning in the ner-
vous system, our knowledge of cerebral ischemic tolerance is 
still in its infancy and insufficient to be able to translate the lab-
oratory results into application. Many issues need to be resolved 
to avoid disappointing results from the clinical application of 
ischemic preconditioning, e.g., whether the tolerant state can be 
maintained long term and provide chronic neuroprotection. Thus 
far, it appears that ischemic tolerance persists for approximately 
1 week in the brain. Are there side effects from the long-term 
expression of ischemic preconditioning-induced genes? The 
threshold for tolerance induction and for cell injury needs to be 
determined. Pharmacological substances used for tolerance in-
duction need to be safe. 
  In conclusion, the past two decades have provided interest-
ing insights into the mechanisms and potential applications of 
ischemic tolerance in the brain. Current knowledge suggests 
that the preconditioning strategy and related interventions, such 
as remote preconditioning and pharmacological precondition-
ing, can protect neurons and improve neuronal survival after 
critical ischemia, and, thus, have promise for practical applica-
tion in cases of vascular neurosurgery and endo-vascular thera-
py and possibly in the management of brain trauma. As knowl-
edge in this field advances, the unresolved issues concerning 
the preconditioning cascade will likely be resolved and will lead 
to pharmacological strategies for protecting the brain from isch-
emic injury, traumatic brain injury, and other neurodegenera-
tive disorders.
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